Development asset linked to Lexeo Therapeutics in public FDA and regional records.
biotech · Alzheimer Disease · Friedreich Ataxia · LXEO
Lexeo Therapeutics
Lexeo Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York, USA HQ
2018 Founded
91 Employees
Public company Type
LXEO · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2018
- Employees
- 91
- Programs
- 3
- Drugs
- 4
- Patents
- 0
Lexeo Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lexeo Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Lexeo Therapeutics in public FDA and regional records.